Canopy Growth Corp. (TSX:WEED): Should This Stock be Your Top Marijuana Pick?

Canopy Growth (TSX:WEED) (NYSE:CGC) continues to hit new highs. Is this the right time to buy the stock?

| More on:
question marks written reminders tickets

Image source: Getty Images

The stock price of Canopy Growth (TSX:WEED) (NYSE:CGC) has doubled in recent weeks, and investors who missed the big rally are wondering if this is still the top stock to buy in the cannabis sector.

Let’s take a look at the current situation to see if Canopy Growth deserves to be in your portfolio.

Canadian market

Through acquisitions and a savvy strategic plan, Canopy Growth has become a leader in the growing Canadian medical marijuana market, and continues to expand its presence. The company has leveraged its position by offering smaller competitors access to its online sales platform, ensuring more medical marijuana patients are exposed to Canopy Growth’s brands, while getting a piece of the action from non-customers and reducing the chances that upstart firms will join together to develop a competing digital sales presence.

As Canada is about to launch its recreational market, Canopy Growth is well positioned to take a large chunk of the sales. The company has supply agreements with a number of provinces and recently acquired Hiku Brands, which owns Tokyo Smoke, DOJA, and Van de Pop brands. Hiku was conditionally awarded four master licenses for retail sales in Manitoba and is recognized as a leader in the market for branded cannabis products.

In addition, the $5 billion investment in Canopy Growth by Constellation Brands last month cements the beverage firm’s commitment to the sector. Constellation now has a 38% interest in Canopy Growth and should be a leader in the anticipated market for cannabis-infused beverages.

Global ambitions

Most investors are focusing on the Canadian market, but Canopy Growth sees significant opportunities worldwide. The company owns a German distribution company and has operations or partnerships set up in Australia, Denmark, Spain, Colombia, Chile, and Brazil, among others.

As governments around the world makes changes to their cannabis rules, Canopy is well positioned to benefit from growing medical marijuana sales, and potentially new recreational markets. Constellation Brands recently reiterated its confidence in the emergence of a global market.

Risks

At the time of writing, Canopy Growth trades at $68 per share, giving the company a market capitalization of about $15 billion. This is extremely expensive for a business that still isn’t profitable and that reported revenue of about $23 million in the most recent quarter.

The stock has been volatile this year, and investors should expect that trend to continue.

Is Canopy Growth the best marijuana stock to own?

Investing in any of the marijuana stocks requires a big leap of faith right now. You have to be of the opinion that the Canadian and global cannabis markets will unfold as expected so that these companies can grow into their valuations.

If you fall in that camp and can handle the wild ride, Canopy Growth is probably the best pick of the lot today. At some point, I think Constellation Brands will take a majority stake given the huge investment it has already made in the company.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Andrew Walker has no position in any stock mentioned.

More on Investing

Hand arranging wood block stacking as step stair with arrow up.
Dividend Stocks

1 Growth Stock With Legit Potential to Outperform the Market

Identifying the stocks that have outperformed the market (in the past) is relatively easy, but selecting the ones that will…

Read more »

healthcare pharma
Tech Stocks

Well Health Stock Is Up 7% After Earnings: What Investors Need to Know

Well Health is benefiting from strong demand as it digitizes healthcare and strives to improve patient outcomes.

Read more »

money cash dividends
Dividend Stocks

Passive Income: The Investment Needed to Yield $1,000 Per Annum

Do you want to generate a juicy passive-income stream? Here's a trio of stocks that can generate a yield of…

Read more »

IMAGE OF A NOTEBOOK WITH TFSA WRITTEN ON IT
Dividend Stocks

Here’s the Average TFSA Balance in 2024

The average TFSA balance has steadily risen over the last six years and surpassed $41,510 in 2023. Will the TFSA…

Read more »

Shopping card with boxes labelled REITs, ETFs, Bonds, Stocks
Dividend Stocks

Invest $10,000 in This Dividend Stock for $1,500.50 in Passive Income

If you have $10,000 to invest, then you likely want a core asset you can set and forget. Which is…

Read more »

Supermarket aisle with empty green shopping cart
Stocks for Beginners

Is Dollarama Stock a Buy?

Dollarama stock (TSX:DOL) has seen shares surge on the back of strong performance and a dividend boost, but it also…

Read more »

potted green plant grows up in arrow shape
Dividend Stocks

TFSA Set and Forget: 2 Dividend-Growth Superstars for the Long Run

I'd look to buy and forget CN Rail (TSX:CNR) and another Canadian dividend-growth sensation for decades at a time.

Read more »

Payday ringed on a calendar
Dividend Stocks

1 Passive-Income Stream and 1 Dividend Stock for $781.48 in Monthly Cash

Looking for passive income? Don't take out a loan with that high interest involved. Instead, consider this method for years…

Read more »